Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 3/20 | 0.37 |
| ▸ | ITPR3 | Q14573 | 9/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.31 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | ENO1 | P06733 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL2026850 | 0.98 | INPP5A (0.36) | INPP5AITPR3SMPD1ITPR2ITPR1 | |
| SCHEMBL6567878 | 0.88 | INPP5A (0.36) | INPP5AITPR3 | |
| SCHEMBL14165319 | 0.84 | INPP5A (0.37) | INPP5AITPR3SMPD1ITPR2ITPR1 | |
| SCHEMBL601363 | 0.84 | GAA (0.41) | INPP5AITPR3SMPD1ITPR2ITPR1 | |
| SCHEMBL14409850 | 0.81 | INPP5A (0.35) | INPP5AITPR3SMPD1 | |
| SCHEMBL29389192 | 0.81 | INPP5A (0.35) | INPP5AITPR3SMPD1 | |
| SCHEMBL5072013 | 0.77 | INPP5A (0.33) | INPP5AITPR3 | |
| SCHEMBL601437 | 0.77 | INPP5A (0.33) | INPP5AITPR3 | |
| SCHEMBL7945649 | 0.76 | INPP5A (0.34) | INPP5A | |
| SCHEMBL10586976 | 0.73 | GAA (0.41) | INPP5AITPR3SMPD1ITPR2ITPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2025-02-06 | — | — | US | claimed |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2024-12-19 | — | — | US | claimed |
| WO-2023229323-A1 | METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVE | 일동제약(주) | 2023-11-30 | — | — | WO | claimed |
| US-20230203091-A1 | GLYCOCONJUGATION PROCESS | PFIZER (US) | 2023-06-29 | — | — | US | claimed |
| CN-115710701-A | Chemical gold plating solution and application | 广东东硕科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| WO-2022264971-A1 | METHOD FOR EVALUATING QUALITY OF SPERM | 国立大学法人東海国立大学機構 | 2022-12-22 | — | — | WO | claimed |
| US-20220378767-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2022-12-01 | — | — | US | claimed |
| US-20220378771-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2022-12-01 | — | — | US | claimed |
| EP-3065944-B1 | MODIFICATION OF POLYAMIDES | ARKEMA INC (US) | 2022-01-19 | — | — | EP | claimed |
| US-20210371453-A1 | GLYCOCONJUGATION PROCESS | PFIZER INC. | 2021-12-02 | — | — | US | claimed |
| US-20130296599-A1 | PHENYLGLYOXYLIC ACID DERIVATIVES AND THEIR PREPARATION AND USE | VTV THERAPEUTICS LLC | 2013-11-07 | — | — | US | claimed |
| EP-2324045-A2 | PHOTO-CROSSLINKED NUCLEIC ACID HYDROGELS | Cornell University (US) | 2011-05-25 | — | — | EP | claimed |
| US-20100240700-A1 | PROPHYLACTIC PRETREATMENT WITH ANTIOXIDANTS | MITOS PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | claimed |
| US-20100041716-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING HYPERCHOLESTEROLEMIA | MITOS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | claimed |
| WO-2010017264-A2 | PHOTO-CROSSLINKED NUCLEIC ACID HYDROGELS | CORNELL UNIVERSITY (US) | 2010-02-11 | — | — | WO | claimed |
| US-6265499-B1 | POLYMERIZING MIXTURE | MENICON CO., LTD. (JP) | 2001-07-24 | — | — | US | claimed |
| EP-0983334-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | Call, Krimhild (DE) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051772-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | CALL, KRIMHILD (DE) | 1998-11-19 | — | — | WO | claimed |
| EP-0327263-B1 | Hair growth stimulation with nitroxide and other radicals | PROCTOR PETER H (US) | 1994-09-07 | — | — | EP | claimed |
| WO-1988005653-A1 | TOPICAL COMPOSITION FOR STIMULATING HAIR GROWTH WITH STABLE FREE RADICALS | PROCTOR PETER H (US) | 1988-08-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041716-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING HYPERCHOLESTEROLEMIA | TXNRD2, TET1, TXNRD3 | INPP5A 3473/4885ITPR3 3453/4885SMPD1 763/4885 |
| US-20220378767-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | TXNRD2, TXN2, TXNRD1 | INPP5A 3802/4885ITPR3 4042/4885SMPD1 1694/4885 |
| US-20130296599-A1 | PHENYLGLYOXYLIC ACID DERIVATIVES AND THEIR PREPARATION AND USE | HPD, GRHPR, AGXT | INPP5A 699/4885ITPR3 4323/4885SMPD1 4315/4885 |
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HMOX2, QSOX1, GPX1 | INPP5A 4208/4885ITPR3 4622/4885SMPD1 997/4885 |
| US-20100240700-A1 | PROPHYLACTIC PRETREATMENT WITH ANTIOXIDANTS | GPX1, GPX4, SOD1 | INPP5A 2729/4885ITPR3 3895/4885SMPD1 1145/4885 |
| US-20220378771-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HMOX2, QSOX1, GPX1 | INPP5A 4208/4885ITPR3 4622/4885SMPD1 997/4885 |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | TXNRD2, TXN2, TXNRD1 | INPP5A 3802/4885ITPR3 4042/4885SMPD1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.